Yamada Sirikan, Wongwanakul Pallapa
Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Med Assoc Thai. 2012 Mar;95(3):349-57.
After therapeutic endoscopy is performed in high-risk patients with peptic ulcer bleeding, rebleeding occurs in about 25 to 30%. High dose intravenous proton pump inhibitors (PPI) have been recommended for the use in high-risk patients to prevent rebleeding following successful therapeutic endoscopy.
Compare the efficacy between pantoprazole high dose bolus injections and continuous intravenous infusion to prevent rebleeding in peptic ulcer patients after initial hemostasis is achieved by the therapeutic endoscopy.
A clinical block randomized control trial was conducted at Maharaj Nakorn Chiang Mai Hospital in massive peptic ulcer bleeding patients. All patients underwent endoscopic diagnosis and treatment within six hours of admission. Hemostasis was achieved by therapeutic endoscopy in 28 patients who received 80 mg pantoprazole as a loading dose before intervention. They were randomized into two groups. The first group was given a high dose of pantoprazole, 40 mg bolus injections twice daily for seven days (n = 13). The second group was given continuous intravenous infusion of pantoprazole, 8 mg per hour for the first three days, followed with a 40 mg bolus injection twice daily similar to the first group from day 4 until day 7 (n = 15). After the seventh day, both groups were given 20 mg of oral pantoprazole once daily for two months. The data was analyzed by Fisher's exact test to compare the frequency of rebleeding within seven days after therapeutic endoscopy.
The frequency of recurrent bleeding between the high dose pantoprazole bolus injection group and the continuous intravenous infusion group was not significantly different, 30.8% and 33.3% respectively (p = 1.0). Three patients in the high dose bolus group and five in the continuous infusion group underwent surgery (p = 0.68). There was no statistically significant difference between the two groups by volume of blood transfusion, length of hospital stay, or mortality.
In the present study, both PPI drug administration methods showed an equally effective for massive peptic ulcer bleeding. Further studies with a larger sample size are recommended.
在对患有消化性溃疡出血的高危患者进行治疗性内镜检查后,再出血发生率约为25%至30%。高剂量静脉注射质子泵抑制剂(PPI)已被推荐用于高危患者,以预防治疗性内镜检查成功后再出血。
比较泮托拉唑高剂量推注与持续静脉输注在治疗性内镜检查实现初始止血后预防消化性溃疡患者再出血的疗效。
在清迈玛哈叻医院对大量消化性溃疡出血患者进行了一项临床区组随机对照试验。所有患者在入院后6小时内接受内镜诊断和治疗。28例患者在干预前接受80mg泮托拉唑作为负荷剂量,通过治疗性内镜检查实现止血。他们被随机分为两组。第一组给予高剂量泮托拉唑,每日两次40mg推注,共7天(n = 13)。第二组给予泮托拉唑持续静脉输注,前三天每小时8mg,从第4天到第7天与第一组一样每日两次40mg推注(n = 15)。第7天后,两组均给予每日一次20mg口服泮托拉唑,持续两个月。通过Fisher精确检验分析数据,以比较治疗性内镜检查后7天内再出血的频率。
高剂量泮托拉唑推注组和持续静脉输注组的再出血频率无显著差异,分别为30.8%和33.3%(p = 1.0)。高剂量推注组3例患者和持续输注组5例患者接受了手术(p = 0.68)。两组在输血量、住院时间或死亡率方面无统计学显著差异。
在本研究中,两种PPI给药方法对大量消化性溃疡出血均显示出同等疗效。建议进行更大样本量的进一步研究。